Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
Upstream Bio’s verekitug is seen as a promising treatment for asthma, targeting the IL-13/TSLP axis, an area validated by Sanofi’s lunsekimig data. Analyst Kate Dellorusso from LifeSci Capital maintained a Buy rating and a $42.00 price target, citing verekitug's robust efficacy in the VALIANT trial and the potential for even stronger results with longer treatment. The company’s differentiated profile, funding runway, and upcoming data catalysts suggest a favorable risk-reward for investors.
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75
Piper Sandler has reiterated its Buy rating on UpStream Bio (UPB.US) and maintained its price target of $75. This continued positive outlook suggests strong confidence in the company's future performance.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received a "Moderate Buy" consensus recommendation from five analysts, with an average one-year price target of $39.00. Despite this, analyst views are mixed, with recent actions including both downgrades and upgrades. The company's fundamentals signal risk, including an EPS miss and negative margins, with the stock currently trading around $8.67.
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) from "hold" to "sell," leading to an 11.4% drop in share price. Despite this, the consensus analyst rating remains a "Moderate Buy" with an average price target of $39.00. The company recently reported a Q1 EPS of -$0.79, missing estimates, and exhibits negative profitability metrics, with analysts expecting a full-year EPS of -4.3.
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program
Upstream Bio (NASDAQ: UPB) has established an at-the-market (ATM) equity program, allowing it to offer and sell up to $150 million worth of its common stock through Leerink Partners LLC. This program provides the company with flexible access to capital, enabling sales of shares over time based on market conditions. Leerink Partners will receive a commission of up to 3.0% of the gross proceeds from these sales, and neither party is obligated to sell a minimum amount of shares.
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
Upstream Bio Inc. (UPB) has completed its VALIANT Phase 2 study for verekitug (UPB-101), an injectable antibody drug aimed at reducing severe asthma attacks in adults. The trial's objective was to assess the drug's efficacy in cutting flare-ups, improving lung function, and controlling daily symptoms, while also monitoring safety. The completion of this study marks a significant milestone, and investors are now anticipating the release of data, which could influence UPB's valuation and strategic position in the competitive asthma biologics market.
Upstream Bio (NASDAQ: UPB) files ATM to raise up to $150M via Leerink
Upstream Bio (NASDAQ: UPB) has filed an at-the-market (ATM) offering to raise up to $150 million by selling shares of its common stock through Leerink Partners LLC. The biopharmaceutical company plans to use the net proceeds primarily for research and clinical development of its product candidates and for general corporate purposes. This flexible offering allows sales from time to time, with Leerink Partners receiving up to 3.0% commission on gross proceeds.
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line
Evercore has downgraded Upstream Bio (NASDAQ:UPB) from "outperform" to "in-line," setting a $15 target price which implies a 53% upside. This comes as the company missed quarterly EPS estimates and shows highly negative profitability, despite a "Moderate Buy" average rating from other analysts with a $39.00 average target price. Upstream Bio's stock trades at $9.79 with a market capitalization of $529.05 million, and its recent earnings report showed negative return on equity and net margin.
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts
Evercore ISI downgraded Upstream Bio (NASDAQ:UPB) to In Line from Outperform and slashed its price target due to a lack of near-term value-inflecting catalysts, ongoing financing concerns, and uncertainty surrounding its COPD trial. Despite acknowledging the long-term potential of verekitug, the firm recommends moving to the sidelines, expecting shares to trade in line with the broader biotech sector. The company is also facing significant cash burn and its stock is deemed overvalued by InvestingPro.
Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40
Evercore ISI has downgraded Upstream Bio's stock rating from Outperform to In Line and significantly reduced its price target from $40 to $15. This change indicates a less optimistic outlook on the biotechnology company, which is developing treatments for inflammatory diseases. Upstream Bio's stock (UPB) is currently trading at $8.750, having experienced a substantial year-to-date decline.
Upstream Bio, Inc. Enters At-the-Market Sales Agreement with Leerink Partners LLC for Common Stock Offering
Upstream Bio, Inc. (UPB) has entered into an At-the-Market (ATM) sales agreement with Leerink Partners LLC, allowing the company to offer and sell shares of its common stock on The Nasdaq Global Select Market. This agreement provides Upstream Bio with a flexible mechanism to raise capital for general corporate purposes, but investors should be aware of potential share dilution. The company affirms compliance with all relevant SEC regulations and will disclose further details in future filings.
According to the latest filing with the SEC, biotechnology company Upstream Bio Inc has entered into a sales agreement with Leerink Partners LLC and plans to raise up to 150 millions dollars by publicly offering common shares.
Upstream Bio Inc, a biotechnology company, has partnered with Leerink Partners LLC to raise up to $150 million through a public offering of common shares. This strategic move aims to fund the accelerated clinical development of its core pipeline drugs for inflammatory diseases and expand its operational capabilities. The collaboration highlights investor confidence in the future prospects of innovative pharmaceutical companies and will be closely watched by the market.
Upstream Bio Launches $150 Million At-The-Market Program
Upstream Bio, Inc. has initiated a $150 million "at-the-market" (ATM) equity program with Leerink Partners LLC, allowing the company to sell shares periodically to raise capital. This flexible financing option provides incremental access to funds, though it may lead to shareholder dilution. The ATM offering is supported by an effective automatic shelf registration statement and comes with a recent analyst rating of "Buy" with a $42.00 price target.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio has highlighted its Phase 3 development strategy for verekitug, focusing on a high-dose quarterly regimen to maximize efficacy in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) without biomarker restriction. The company announced plans to initiate dosing in Phase 3 trials for both indications in Q1 2027, following positive Phase 2 results for verekitug. Upstream Bio also reported a strong cash position of $341.5 million at the end of 2025, expected to fund operations through 2027.
Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS
Upstream Bio (NASDAQ:UPB) reported its quarterly earnings, missing the consensus EPS estimate by $0.06 with a loss of ($0.79) per share, despite revenue of $0.67 million beating expectations. The company shares rose 7.9% to $10.22 following the announcement, reflecting a market capitalization of approximately $552.3 million. Analyst ratings are mixed, with a consensus of "Moderate Buy" and a price target of $45.25, while institutional investors have shown varied adjustments to their holdings.
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027
Verekitug, a TSLP receptor antagonist from UPB, has shown strong efficacy and safety in its Phase 2 trials for severe asthma and CRSWNP, supporting quarterly at-home dosing. The success of these trials paves the way for Phase 3 trials, which are scheduled to commence in Q1 2027, aiming at significant commercial opportunities in respiratory diseases.
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug
Upstream Bio, Inc. has announced its financial results for Q4 and full year 2025 and outlined its Phase 3 development strategy for its lead asset, verekitug. This marks a crucial progression in the company's clinical pipeline. CEO Rand Sutherland has also participated in recent healthcare conferences, engaging in fireside chats to discuss the company's advancements.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio has highlighted its Phase 3 development strategy for verekitug, focusing on a high-dose quarterly regimen for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate dosing in Q1 2027. The company reported positive Phase 2 results for verekitug in severe asthma and CRSwNP, demonstrating significant improvements and a favorable safety profile. Upstream Bio also announced its financial results for Q4 and full year 2025, with a strong cash position of $341.5 million expected to fund operations through 2027.
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy
Upstream Bio reported a widened net loss of $42.5 million for Q4 2025 due to increased research and development spending on verekitug, compared to a $21.2 million loss in the prior year. Despite the larger loss, the company is making strong clinical progress, with positive Phase 2 data for verekitug in severe asthma and CRSwNP supporting its advancement into Phase 3 trials in Q1 2027. Upstream Bio maintains a strong cash position of $341.5 million, expected to fund operations through 2027.
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027
Upstream Bio announced plans to initiate Phase 3 clinical trials for its asthma and rhinosinusitis drug, verekitug, in Q1 2027. This follows positive Phase 2 results for severe asthma and chronic rhinosinusitis with nasal polyps, showing significant reductions in exacerbation rates and polyp scores. Despite positive clinical developments and strong analyst price targets, the company reported a net loss of $42.5 million for Q4 2025 and its stock has declined 45% over the past six months, though it maintains a strong cash position.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $341.5 million. The company is advancing its Phase 3 development strategy for verekitug, an investigational drug targeting TSLP receptor, for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate dosing in Q1 2027. This strategy is based on positive Phase 2 VALIANT trial results in severe asthma and VIBRANT trial analyses in CRSwNP, showing significant efficacy and a favorable safety profile for a high-dose quarterly regimen.
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index
Upstream Bio, Inc. (NasdaqGS: UPB) has been removed from the S&P Biotechnology Select Industry Index. This news follows several recent developments for the company, including reports on its asthma and chronic rhinosinusitis with nasal polyps drug trials, and a previous addition to the NASDAQ Biotechnology Index. Analysts currently have an average target price significantly higher than its last close price.
Upstream Bio Inc expected to post a loss of 70 cents a share - Earnings Preview
Upstream Bio Inc is projected to report a loss of 70 cents per share, according to an earnings preview. This information was released by Refinitiv and originally reported by Reuters. The company's stock symbol is UPB.
Tax-related stock sale by Upstream Bio (UPB) chief business officer
Upstream Bio's Chief Business Officer, Adam Houghton, reported an automatic sale of 699 shares of common stock at $9.29 per share. This transaction was executed to satisfy tax withholding obligations on vested restricted stock units, adhering to the company's "sell-to-cover" policy. After this sale, Houghton directly holds 24,301 shares of Upstream Bio common stock.
Tax-withholding share sale by Upstream Bio (UPB) General Counsel disclosed
Upstream Bio's General Counsel, Allison Ambrose, reported an automatic sale of 475 shares of common stock at $9.29 per share. This transaction was executed under the company's "sell-to-cover" policy to satisfy tax withholding obligations on vested restricted stock units, not as a discretionary market trade. Following the sale, Ambrose directly holds 16,525 shares, indicating a minor, tax-related adjustment to her overall holdings.
Upstream Bio CFO Gray sells $7915 in shares
Upstream Bio's CFO and COO, Michael Gray, sold 852 shares of common stock for $7,915 to cover tax withholding obligations. The sale occurred while the stock traded above the company's estimated Fair Value. Upstream Bio, a biotech company, is burning through cash and recently reported mixed results from its Phase 2 VALIANT trial for an asthma treatment.
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale
Upstream Bio CEO Sutherland Everett Rand recently sold 2,093 shares of the company's stock, valued at $19,443. This transaction comes as Upstream Bio's shares reacted positively to new Phase 2 Vibrant trial data for verekitug, reinforcing the drug's efficacy. TipRanks' AI Analyst, Spark, rates UPB as "Neutral," citing strong technical momentum but tempered by early-stage biotech's typical weak financial performance.
Upstream Bio (NasdaqGS:UPB) Stock Forecast & Analyst Predictions
Upstream Bio (NasdaqGS:UPB) is forecast to experience declining earnings at 11.1% per annum, yet its revenue is expected to grow significantly at 62.7% per year, outpacing the US market. The company is projected to remain unprofitable over the next three years with a negative return on equity. Recent updates include positive Phase 2 trial results for Verekitug in severe asthma and chronic rhinosinusitis, despite facing competition and share price stability risks.
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB
Integral Health Asset Management LLC has acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the third quarter, purchasing 575,000 shares valued at approximately $10.816 million, representing 1.06% ownership. Analyst ratings for Upstream Bio are mixed but lean positive, with a consensus "Moderate Buy" rating and a price target of $45.25. The stock opened at $9.23, trading below its 50-day and 200-day moving averages, with a market capitalization of about $498.8 million.
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing
Upstream Bio's (UPB) verekitug showed strong efficacy and supports quarterly dosing in phase II asthma trials. The company plans to initiate phase III trials for severe asthma and CRSwNP early next year, while its COPD program is over 60% enrolled. Upstream Bio has a cash runway extending through 2027.
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts
Upstream Bio, Inc. CEO Rand Sutherland is scheduled to participate in a live fireside chat at the TD Cowen 46th Annual Healthcare Conference. The event, taking place at 9:50 a.m. ET, will be available via live stream, with a replay accessible on the company's investor relations website. This appearance is part of Upstream Bio's ongoing efforts to engage investors and provide strategic insights from its leadership.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received an average "Moderate Buy" rating from five analysts, with a consensus one-year price target of $45.25. The company's shares opened at $7.70, significantly below their 12-month high of $33.68, and have a market capitalization of approximately $416 million. Institutional investors like Bain Capital Life Sciences and Geode Capital Management have increased their stakes, while Norges Bank initiated a new position, indicating growing investor interest despite the stock's current low trading price and high volatility.
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday
Upstream Bio (NASDAQ: UPB) is anticipated to release its Q4 2025 earnings before the market opens on Wednesday, March 11th, with analysts forecasting a loss of ($0.73) per share. The company's stock, which opened at $7.36, has a "Moderate Buy" consensus rating and an average target price of $45.25 from analysts. Upstream Bio is a clinical-stage biotechnology company focusing on next-generation prophylactic vaccines and immuno-oncology therapies using a proprietary viral vector platform.
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
Upstream Bio reported that its primary endpoint showed a reduction of -1.95 in the Nasal Polyp Score. This brief news update was provided by Reuters via Refinitiv.
Sinus polyp drug trial cuts need for surgery, steroids by 76%
Upstream Bio presented additional Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), showing a 76% reduction in the need for surgery or systemic corticosteroids and significant improvements in nasal polyp and congestion scores. The drug, administered every 12 weeks, demonstrated a favorable safety profile with no serious adverse events. Upstream Bio plans to advance verekitug into Phase 3 registrational trials for CRSwNP and severe asthma.
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio (Nasdaq:UPB) presented additional positive data from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the 2026 AAAAI Annual Meeting. New analyses, adjusting for rescue therapy use, showed an improved placebo-adjusted reduction in endoscopic nasal polyp score (-1.95, p < 0.0001) and nasal congestion score (-0.96, p < 0.0001). These results reinforce verekitug's strong efficacy and differentiated profile, with future Phase 3 trials planned for CRSwNP and severe asthma.
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score
Upstream Bio, Inc. announced that its primary endpoint showed a reduction of -1.95 in nasal polyp scores. This news comes ahead of additional analyses from their Phase 2 Vibrant trial in Chronic Rhinosinusitis with Nasal Polyps, which will be presented at the AAAAI Annual Meeting in 2026. The company is actively developing verekitug, a treatment targeting the TSLP receptor for inflammatory diseases, including severe asthma and chronic rhinosinusitis with nasal polyps.
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio announced additional analyses from its Phase 2 VIBRANT trial for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), which confirmed strong efficacy with a new statistical approach accounting for rescue therapy use. The data, presented at the AAAAI 2026 Annual Meeting, showed significant reductions in nasal polyp score and nasal congestion, supporting verekitug's potential as a less-frequent dosing option for CRSwNP and leading to plans for Phase 3 trials.
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026
Upstream Bio, Inc. has presented new analyses from its VIBRANT Phase 2 trial for verekitug, targeting chronic rhinosinusitis with nasal polyps, at the AAAAI2026 conference. This presentation adds to previously released data, offering further insights into the drug's efficacy and safety for this condition. The research aims to address current treatment gaps and improve the quality of life for patients.
UPB Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of UpStream Bio Inc. (UPB), including its income statement, balance sheet, cash flow statement, and key financial ratios. It highlights that UPB recorded $2.4M in revenue and a net income of -$62.8M in fiscal year 2024, indicating low profitability and earnings quality. The company shows strong liquidity and low leverage but faces challenges in profitability and growth.
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector
Upstream Bio, Inc. (UPB) is a clinical-stage biotech company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's stock shows a significant potential upside of 505.79% based on an average target price of $47.86, despite current losses and heavy R&D investment. Analysts are overwhelmingly positive, with eight buy ratings.
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Upstream Bio, Inc. announced that it will present additional analyses from its Phase 2 VIBRANT trial of verekitug for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) at the AAAAI Annual Meeting 2026. The presentation will occur on March 1, 2026, and will focus on the efficacy and safety of verekitug, a novel TSLP receptor antagonist, with an emphasis on adjustments for concomitant rescue therapy use. This underscores the company's ongoing development of verekitug for inflammatory diseases, including severe respiratory disorders.
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com
Upstream Bio Inc. (NASDAQ:UPB) will present new analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the American Academy of Allergy, Asthma and Immunology Congress 2026. This presentation will focus on the drug's efficacy adjusted for concomitant rescue therapy. Despite a significant drop from its 52-week high, UPB shares are considered undervalued by InvestingPro, with analysts maintaining optimistic price targets.
Upstream Bio to Present Additional Analyses from Phase 2
Upstream Bio will present additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the AAAAI Annual Meeting 2026. The presentation will include new efficacy data adjusted for concomitant rescue therapy use. Verekitug is an investigational antibody targeting the TSLP receptor, a key driver of inflammatory diseases.
Upstream Bio announces participation in major healthcare conferences
Upstream Bio's CEO, Rand Sutherland, MD, is scheduled to participate in fireside chats at two major healthcare conferences: the TDCowen Health Care Conference on March 4 and the LeerinkPartners Global Healthcare Conference on March 9. His appearances underscore the company's commitment to engaging in critical industry discussions.
Peering Into Upstream Bio Inc's Recent Short Interest
Upstream Bio Inc's (NYSE: UPB) short interest as a percent of float has decreased by 7.73% since its last report, indicating a potential shift towards a more bullish sentiment among investors. Currently, 3.18 million shares are sold short, representing 10.62% of the available regular shares. This short interest level is lower than the peer group average of 14.45%, suggesting less bearish sentiment compared to similar companies.
Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company, announced its CEO, Rand Sutherland, MD, will participate in two upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The company is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, with its lead candidate verekitug.
Peering Into Upstream Bio Inc's Recent Short Interest
Upstream Bio Inc's short interest has decreased by 7.73%, with 3.18 million shares currently sold short, representing 10.62% of its tradable shares. This decline suggests a more bullish sentiment from investors. Compared to its peers, Upstream Bio Inc has less short interest, averaging 10.62% versus the peer group average of 14.45%.
Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio, a clinical-stage biotechnology company, announced its CEO, Rand Sutherland, MD, will participate in two upcoming investor conferences in March: the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Partners Global Healthcare Conference. The company is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, with its lead candidate verekitug. Live webcasts of these presentations will be available on Upstream Bio's investor relations website.
Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio, a clinical-stage company focusing on inflammatory diseases, announced its CEO, Rand Sutherland, MD, will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The company is developing verekitug, an antagonist targeting the TSLP receptor, for severe respiratory disorders including chronic rhinosinusitis with nasal polyps, severe asthma, and COPD. Webcasts of the presentations will be available on Upstream Bio's investor website.
